ACCESSWIRE
13 May 2022, 04:13 GMT+10
MILAN, ITALY / ACCESSWIRE / May 12, 2022 / Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today a €3.5 million seed investment in NanoPhoria, a pre-clinical stage biotech company that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles.
The investment was made through the Sofinnova Telethon Fund, the venture capital firm's early-stage strategy focused mainly on investments in rare and genetic diseases, and the largest fund entirely dedicated to biotechnology in Italy.
The lead product coming out of the platform is a treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide.
Nanophoria was co-founded by Dr. Daniele Catalucci, Research Director at the Institute of Genetic and Biomedical Research (IRGB), National Research Council (CNR); Dr. Michele Iafisco, Senior Researcher at the Institute of Science and Technology for Ceramics (ISTEC), National Research Council; Dr. Alessio Alogna, Cardiologist and Clinical Scientist at Charité Universitätsmedizin Berlin; and the CEO, Claudio De Luca, a life science executive with more than 25 years of experience in leadership positions in medtech and biotech
'NanoPhoria is developing a cutting-edge approach for a non-viral delivery of biologics, targeted to the heart, and can count on a team of four co-founders whose skills are complimentary, with scientific, medical and industrial experience,' said Lucia Faccio, a Partner with the Sofinnova Telethon Fund. 'They are all actively involved in the management of the company.'
The company, whose versatile platform allows selective targeting at the organ and/or cellular level, has been officially recognized as a spin-off of CNR, the largest multidisciplinary public research institution in Italy.
NanoPhoria will be presenting at the upcoming BioEquity conference, Europe's premier meeting of investors and biopharma executives, which will take place in Milan from May 16-18.
'We are pleased to have the support of Sofinnova Telethon Fund as we work to consolidate our nano-delivery platform and advance our first product towards the clinic,' said Claudio De Luca, CEO and co-founder of NanoPhoria. 'Our collaboration has already proved very positive. It will
strongly contribute to the acceleration of our development programs and help us bring effective therapies to patients and address unmet clinical needs.'
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
About NanoPhoria
NanoPhoria is a biotech company based in Milan that is developing a versatile, non-viral drug delivery platform based on inorganic nanoparticles. The company's first product is a pre-clinical stage treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide. The company, whose four founders have active roles and complimentary backgrounds, is a spin-off from CNR, the largest public research institution in Italy.
Media Contacts
NanoPhoria
Daniele Catalucci, Chief Scientific Officer
daniele.catalucci@nanophoria.com
Havas PR Milan
Pierluigi Cavarai
pierluigi.cavarai-ext@havaspr.com
+39 (0) 392 7799933
SOURCE: Sofinnova Partners
Get a daily dose of Boston Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Boston Star.
More InformationMOSCOW, Russia: Russia's consumer price index has fallen by 0.12 percent for the third consecutive week.This drop in the consumer ...
TAIPEI, Taiwan: The American Chamber of Commerce in Taiwan has recommended that the United States "urgently" initiate talks with Taiwan ...
NEW YORK, New York - Stocks on Wall Street and around the globe rallied hard on Friday pushing the major ...
DETROIT, Michigan: Detroit's three big automakers - General Motors, Ford and Chrysler parent Stellantis NV - have announced that wearing ...
HONG KONG: To cope with the weakening property market, developers in China are coming up with innovative ways to attract ...
SYDNEY, NSW, Australia - Stocks in Asia made solid gains on Friday in a positive end to the week.In Japan, ...
BOSTON, Massachusetts: U.S. airlines were forced to cancel over 2,800 flights late last week after the Northeast was buffeted by ...
Major League Baseball suspended Toronto Blue Jays hitting coach Guillermo Martinez five games on Friday for making contact with an ...
The Los Angeles Valiant completed a reverse sweep to beat the Philadelphia Fusion on Friday in the Overwatch League's Midseason ...
A clash between North Carolina and Indiana will highlight this fall's ACC/Big Ten Challenge. The games will air between Nov. ...
History will favor Chicago Cubs pitcher Kyle Hendricks when he faces the St. Louis Cardinals on Friday. Hendricks is 12-3 ...
Catching the New York Yankees in the American League East might be unlikely, but the Boston Red Sox are back ...